{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:58:13Z","timestamp":1792000693976,"version":"4.4.0"},"reference-count":158,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T00:00:00Z","timestamp":1664150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006955","name":"Office of Extramural Research, National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006955","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Physiol."],"abstract":"<jats:p>Hypertrophic cardiomyopathy (HCM) affects more than 1 in 500 people in the general population with an extensive burden of morbidity in the form of arrhythmia, heart failure, and sudden death. More than 25\u00a0years since the discovery of the genetic underpinnings of HCM, the field has unveiled significant insights into the primary effects of these genetic mutations, especially for the myosin heavy chain gene, which is one of the most commonly mutated genes. Our group has studied the molecular effects of HCM mutations on human \u03b2-cardiac myosin heavy chain using state-of-the-art biochemical and biophysical tools for the past 10\u00a0years, combining insights from clinical genetics and structural analyses of cardiac myosin. The overarching hypothesis is that HCM-causing mutations in sarcomere proteins cause hypercontractility at the sarcomere level, and we have shown that an increase in the number of myosin molecules available for interaction with actin is a primary driver. Recently, two pharmaceutical companies have developed small molecule inhibitors of human cardiac myosin to counteract the molecular consequences of HCM pathogenesis. One of these inhibitors (mavacamten) has recently been approved by the FDA after completing a successful phase III trial in HCM patients, and the other (aficamten) is currently being evaluated in a phase III trial. Myosin inhibitors will be the first class of medication used to treat HCM that has both robust clinical trial evidence of efficacy and that targets the fundamental mechanism of HCM pathogenesis. The success of myosin inhibitors in HCM opens the door to finding other new drugs that target the sarcomere directly, as we learn more about the genetics and fundamental mechanisms of this disease.<\/jats:p>","DOI":"10.3389\/fphys.2022.975076","type":"journal-article","created":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T00:53:22Z","timestamp":1664153602000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":58,"title":["Hypertrophic cardiomyopathy: Mutations to mechanisms to therapies"],"prefix":"10.3389","volume":"13","author":[{"given":"Masataka","family":"Kawana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Spudich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen M.","family":"Ruppel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1093\/cvr\/cvr015","article-title":"Mitochondrial adaptations to physiological vs. pathological cardiac hypertrophy","volume":"90","author":"Abel","year":"2011","journal-title":"Cardiovasc. Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1016\/j.celrep.2016.11.040","article-title":"Early-onset hypertrophic cardiomyopathy mutations significantly increase the velocity, force, and actin-activated ATPase activity of human \u03b2-cardiac myosin","volume":"17","author":"Adhikari","year":"2016","journal-title":"Cell. Rep."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1038\/s41467-019-10555-9","article-title":"\u03b2-Cardiac myosin hypertrophic cardiomyopathy mutations release sequestered heads and increase enzymatic activity","volume":"10","author":"Adhikari","year":"2019","journal-title":"Nat. Commun."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1073\/pnas.1516732113","article-title":"Titin strain contributes to the Frank\u2013Starling law of the heart by structural rearrangements of both thin- and thick-filament proteins","volume":"113","author":"Ait-Mou","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B5","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.celrep.2015.04.006","article-title":"Ensemble force changes that result from human cardiac myosin mutations and a small-molecule effector","volume":"11","author":"Aksel","year":"2015","journal-title":"Cell. Rep."},{"key":"B6","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1172\/JCI116957","article-title":"Prognostic implications of novel beta cardiac myosin heavy chain gene mutations that cause familial hypertrophic cardiomyopathy","volume":"93","author":"Anan","year":"1994","journal-title":"J. Clin. Investig."},{"key":"B7","doi-asserted-by":"publisher","first-page":"E8143-E8152","DOI":"10.1073\/pnas.1809540115","article-title":"Deciphering the super relaxed state of human \u03b2-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers","volume":"115","author":"Anderson","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B8","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1161\/CIRCRESAHA.111.242974","article-title":"Disease pathways and novel therapeutic targets in hypertrophic cardiomyopathy","volume":"109","author":"Ashrafian","year":"2011","journal-title":"Circ. Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0168-9525(03)00081-7","article-title":"Hypertrophic cardiomyopathy:a paradigm for myocardial energy depletion","volume":"19","author":"Ashrafian","year":"2003","journal-title":"Trends Genet."},{"key":"B10","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/157368a0","article-title":"Tropomyosin : A new asymmetric protein component of muscle","volume":"157","author":"Bailey","year":"1946","journal-title":"Nature"},{"key":"B11","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/415198a","article-title":"Cardiac excitation\u2013contraction coupling","volume":"415","author":"Bers","year":"2002","journal-title":"Nature"},{"key":"B12","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1196\/annals.1341.008","article-title":"Calcium signaling in cardiac ventricular myocytes","volume":"1047","author":"Bers","year":"2005","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"B13","doi-asserted-by":"publisher","first-page":"17713","DOI":"10.1073\/pnas.0606741103","article-title":"Crystal structures of human cardiac \u2424-myosin II S2-\u232c provide insight into the functional role of the S2 subfragment","volume":"103","author":"Blankenfeldt","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B14","doi-asserted-by":"publisher","first-page":"5158","DOI":"10.1074\/jbc.M113.511204","article-title":"The hypertrophic cardiomyopathy myosin mutation R453C alters ATP binding and hydrolysis of human cardiac \u03b2-myosin","volume":"289","author":"Bloemink","year":"2014","journal-title":"J. Biol. Chem."},{"key":"B15","doi-asserted-by":"publisher","first-page":"8177","DOI":"10.1073\/pnas.1920632117","article-title":"Myosin filament-based regulation of the dynamics of contraction in heart muscle","volume":"117","author":"Brunello","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B16","doi-asserted-by":"publisher","first-page":"14142","DOI":"10.1021\/acs.jmedchem.1c01290","article-title":"Discovery of aficamten (CK-274), a next-generation cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy","volume":"64","author":"Chuang","year":"2021","journal-title":"J. Med. Chem."},{"key":"B17","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/S0140-6736(11)61126-4","article-title":"The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: A double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial","volume":"378","author":"Cleland","year":"2011","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1002\/ar.22973","article-title":"Structural implications of \u03b2-cardiac myosin heavy chain mutations in human disease: Cardiac myosin mutations and disease","volume":"297","author":"Colegrave","year":"2014","journal-title":"Anat. Rec."},{"key":"B19","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s12551-011-0044-9","article-title":"The role of the myosin ATPase activity in adaptive thermogenesis by skeletal muscle","volume":"3","author":"Cooke","year":"2011","journal-title":"Biophys. Rev."},{"key":"B20","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s00424-013-1426-6","article-title":"Structure, sarcomeric organization, and thin filament binding of cardiac myosin-binding protein-C","volume":"466","author":"Craig","year":"2014","journal-title":"Pflugers Arch."},{"key":"B21","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.sbi.2006.03.006","article-title":"Structure and function of myosin filaments","volume":"16","author":"Craig","year":"2006","journal-title":"Curr. Opin. Struct. Biol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1023\/A:1018613907574","article-title":"The in vitro motility activity of \u03b2-cardiac myosin depends on the nature of the \u03b2-myosin heavy chain gene mutation in hypertrophic cardiomyopathy","volume":"18","author":"Cuda","year":"1997","journal-title":"J. Muscle Res. Cell. Motil."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/j.cell.2016.04.002","article-title":"A tension-based model distinguishes hypertrophic versus dilated cardiomyopathy","volume":"165","author":"Davis","year":"2016","journal-title":"Cell."},{"key":"B24","first-page":"157","article-title":"Chapter 6 kinetic and equilibrium analysis of the myosin ATPase","volume-title":"Methods Enzym.","author":"De La Cruz","year":"2009"},{"key":"B25","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ceb.2003.11.011","article-title":"Relating biochemistry and function in the myosin superfamily","volume":"16","author":"De La Cruz","year":"2004","journal-title":"Curr. Opin. Cell. Biol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.yjmcc.2009.12.017","article-title":"Myofilament length dependent activation","volume":"48","author":"de Tombe","year":"2010","journal-title":"J. Mol. Cell. Cardiol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1007\/s00018-012-0927-3","article-title":"Identification of functional differences between recombinant human \u03b1 and \u03b2 cardiac myosin motors","volume":"69","author":"Deacon","year":"2012","journal-title":"Cell. Mol. Life Sci."},{"key":"B28","doi-asserted-by":"publisher","first-page":"H284","DOI":"10.1152\/ajpheart.00128.2007","article-title":"Hypertrophic and dilated cardiomyopathy mutations differentially affect the molecular force generation of mouse \u03b1-cardiac myosin in the laser trap assay","volume":"293","author":"Debold","year":"2007","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1006\/jmcc.2000.1260","article-title":"Malignant hypertrophic cardiomyopathy caused by the Arg723Gly mutation in \u03b2 -myosin heavy chain gene","volume":"32","author":"Enjuto","year":"2000","journal-title":"J. Mol. Cell. Cardiol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"3993","DOI":"10.1073\/pnas.90.9.3993","article-title":"Missense mutations in the beta-myosin heavy-chain gene cause central core disease in hypertrophic cardiomyopathy","volume":"90","author":"Fananapazir","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B31","doi-asserted-by":"publisher","first-page":"a021063","DOI":"10.1101\/cshperspect.a021063","article-title":"Genetics and disease of ventricular muscle","volume":"4","author":"Fatkin","year":"2014","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"a004242","DOI":"10.1101\/cshperspect.a004242","article-title":"Calcium signaling in cardiac myocytes","volume":"3","author":"Fearnley","year":"2011","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/368113a0","article-title":"Single myosin molecule mechanics: Piconewton forces and nanometre steps","volume":"368","author":"Finer","year":"1994","journal-title":"Nature"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1161\/01.RES.0000127175.21818.C2","article-title":"Cardiac myosin binding protein C: Its role in physiology and disease","volume":"94","author":"Flashman","year":"2004","journal-title":"Circ. Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.yjmcc.2012.03.009","article-title":"Increased myofilament Ca2+ sensitivity and diastolic dysfunction as early consequences of Mybpc3 mutation in heterozygous knock-in mice","volume":"52","author":"Fraysse","year":"2012","journal-title":"J. Mol. Cell. Cardiol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1136\/heartjnl-2014-307205","article-title":"Phenotype and prognostic correlations of the converter region mutations affecting the \u03b2 myosin heavy chain","volume":"101","author":"Garc\u00eda-Giustiniani","year":"2015","journal-title":"Heart"},{"key":"B37","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1126\/science.272.5262.731","article-title":"A mouse model of familial hypertrophic cardiomyopathy","volume":"272","author":"Geisterfer-Lowrance","year":"1996","journal-title":"Science"},{"key":"B38","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/0092-8674(90)90274-I","article-title":"A molecular basis for familial hypertrophic cardiomyopathy: A \u03b2 cardiac myosin heavy chain gene missense mutation","volume":"62","author":"Geisterfer-Lowrance","year":"1990","journal-title":"Cell."},{"key":"B39","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/6549","article-title":"The pathogenesis of familial hypertrophic cardiomyopathy: Early and evolving effects from an \u03b1-cardiac myosin heavy chain missense mutation","volume":"5","author":"Georgakopoulos","year":"1999","journal-title":"Nat. Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1126\/science.aad3456","article-title":"A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice","volume":"351","author":"Green","year":"2016","journal-title":"Science"},{"key":"B41","doi-asserted-by":"publisher","first-page":"17403","DOI":"10.1073\/pnas.1009619107","article-title":"Cardiomyopathy-linked myosin regulatory light chain mutations disrupt myosin strain-dependent biochemistry","volume":"107","author":"Greenberg","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B42","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/cm.20441","article-title":"The molecular basis of frictional loads in the in vitro motility assay with applications to the study of the loaded mechanochemistry of molecular motors","volume":"67","author":"Greenberg","year":"2010","journal-title":"Cytoskeleton"},{"key":"B43","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1006\/jmbi.1998.2522","article-title":"Mutations in beta-myosin S2 that cause familial hypertrophic cardiomyopathy (FHC) abolish the interaction with the regulatory domain of myosin-binding protein-C","volume":"286","author":"Gruen","year":"1999","journal-title":"J. Mol. Biol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"13H-18H","DOI":"10.1016\/S0002-9149(99)00251-9","article-title":"Familial hypertrophic cardiomyopathy and atrial fibrillation caused by Arg663His beta\u2013cardiac myosin heavy chain mutation","volume":"83","author":"Gruver","year":"1999","journal-title":"Am. J. Cardiol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"7003","DOI":"10.1074\/jbc.M114.596676","article-title":"Mechanistic heterogeneity in contractile properties of \u03b1-tropomyosin (TPM1) mutants associated with inherited cardiomyopathies","volume":"290","author":"Gupte","year":"2015","journal-title":"J. Biol. Chem."},{"key":"B46","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/nnano.2015.132","article-title":"Mechanical coordination in motor ensembles revealed using engineered artificial myosin filaments","volume":"10","author":"Hariadi","year":"2015","journal-title":"Nat. Nanotechnol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1161\/CIRCRESAHA.110.231670","article-title":"In the thick of it: HCM-causing mutations in myosin binding proteins of the thick filament","volume":"108","author":"Harris","year":"2011","journal-title":"Circ. Res."},{"key":"B48","doi-asserted-by":"publisher","first-page":"e202012729","DOI":"10.1085\/jgp.202012729","article-title":"Making waves: A proposed new role for myosin-binding protein C in regulating oscillatory contractions in vertebrate striated muscle","volume":"153","author":"Harris","year":"2021","journal-title":"J. Gen. Physiol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1016\/j.jacc.2021.09.1381","article-title":"Effect of mavacamten on echocardiographic features in symptomatic patients with obstructive hypertrophic cardiomyopathy","volume":"78","author":"Hegde","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"741","DOI":"10.7326\/M18-3016","article-title":"Mavacamten treatment for obstructive hypertrophic cardiomyopathy: A clinical trial","volume":"170","author":"Heitner","year":"2019","journal-title":"Ann. Intern. Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s10974-019-09567-1","article-title":"MyBP-C: One protein to govern them all","volume":"41","author":"Heling","year":"2020","journal-title":"J. Muscle Res. Cell. Motil."},{"key":"B52","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1161\/CIRCGENETICS.113.000448","article-title":"Sarcomere mutation-specific expression patterns in human hypertrophic cardiomyopathy","volume":"7","author":"Helms","year":"2014","journal-title":"Circ. Cardiovasc. Genet."},{"key":"B53","doi-asserted-by":"publisher","first-page":"e133782","DOI":"10.1172\/jci.insight.133782","article-title":"Effects of MYBPC3 loss-of-function mutations preceding hypertrophic cardiomyopathy","volume":"5","author":"Helms","year":"2020","journal-title":"JCI Insight"},{"key":"B54","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1056\/NEJMoa1110186","article-title":"Truncations of titin causing dilated cardiomyopathy","volume":"366","author":"Herman","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1016\/j.jacc.2020.03.064","article-title":"Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy","volume":"75","author":"Ho","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.1161\/01.CIR.0000019070.70491.6D","article-title":"Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy","volume":"105","author":"Ho","year":"2002","journal-title":"Circulation"},{"key":"B57","doi-asserted-by":"publisher","first-page":"6701","DOI":"10.1073\/pnas.1606950113","article-title":"Multidimensional structure-function relationships in human \u03b2-cardiac myosin from population-scale genetic variation","volume":"113","author":"Homburger","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1016\/j.bpj.2011.02.061","article-title":"A new state of cardiac myosin with very slow ATP turnover: A potential cardioprotective mechanism in the heart","volume":"100","author":"Hooijman","year":"2011","journal-title":"Biophys. J."},{"key":"B59","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.tibs.2016.09.006","article-title":"How myosin generates force on actin filaments","volume":"41","author":"Houdusse","year":"2016","journal-title":"Trends biochem. Sci."},{"key":"B60","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/j.1749-6632.1959.tb49323.x","article-title":"The structural basis of the contraction mechanism in striated muscle","volume":"81","author":"Huxley","year":"1959","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1126\/science.164.3886.1356","article-title":"The mechanism of muscular contraction","volume":"164","author":"Huxley","year":"1969","journal-title":"Science"},{"key":"B62","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.1091\/mbc.e08-02-0206","article-title":"Head\u2013head and head\u2013tail interaction: A general mechanism for switching off myosin II activity in cells","volume":"19","author":"Jung","year":"2008"},{"key":"B63","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1113\/JP275050","article-title":"Omecamtiv mercabil and blebbistatin modulate cardiac contractility by perturbing the regulatory state of the myosin filament","volume":"596","author":"Kampourakis","year":"2018","journal-title":"J. Physiol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1161\/CIRCGENETICS.108.821314","article-title":"Prevalence of sarcomere protein gene mutations in preadolescent children with hypertrophic cardiomyopathy","volume":"2","author":"Kaski","year":"2009","journal-title":"Circ. Cardiovasc. Genet."},{"key":"B65","doi-asserted-by":"publisher","first-page":"e1601959","DOI":"10.1126\/sciadv.1601959","article-title":"Biophysical properties of human \u03b2-cardiac myosin with converter mutations that cause hypertrophic cardiomyopathy","volume":"3","author":"Kawana","year":"2017","journal-title":"Sci. Adv."},{"key":"B66","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/0002-9149(65)90379-6","article-title":"Effect of left ventricular size and shape upon the hemodynamics of subaortic stenosis","volume":"15","author":"Klein","year":"1965","journal-title":"Am. J. Cardiol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1146\/annurev.physiol.67.040403.114025","article-title":"CALCIUM, thin filaments, and the integrative biology of cardiac contractility","volume":"67","author":"Kobayashi","year":"2005","journal-title":"Annu. Rev. Physiol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1113\/jphysiol.2007.135426","article-title":"Influence of enhanced troponin C Ca 2+ -binding affinity on cooperative thin filament activation in rabbit skeletal muscle: sTnC Ca 2+ -binding properties and cooperative thin filament activation","volume":"583","author":"Kreutziger","year":"2007","journal-title":"J. Physiol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"6272","DOI":"10.1073\/pnas.83.17.6272","article-title":"Fluorescent actin filaments move on myosin fixed to a glass surface","volume":"83","author":"Kron","year":"1986","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B70","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s10974-011-9280-7","article-title":"Cardiac myosin binding protein C phosphorylation in cardiac disease","volume":"33","author":"Kuster","year":"2012","journal-title":"J. Muscle Res. Cell. Motil."},{"key":"B71","doi-asserted-by":"publisher","first-page":"E1991-E2000","DOI":"10.1073\/pnas.1715247115","article-title":"Interacting-heads motif has been conserved as a mechanism of myosin II inhibition since before the origin of animals","volume":"115","author":"Lee","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B72","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1161\/CIRCULATIONAHA.112.139717","article-title":"Titin is a major human disease gene","volume":"127","author":"LeWinter","year":"2013","journal-title":"Circulation"},{"key":"B73","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/s41594-018-0069-x","article-title":"Controlling load-dependent kinetics of \u03b2-cardiac myosin at the single-molecule level","volume":"25","author":"Liu","year":"2018","journal-title":"Nat. Struct. Mol. Biol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"13185","DOI":"10.1074\/jbc.M800757200","article-title":"Unc45 activates hsp90-dependent folding of the myosin motor domain","volume":"283","author":"Liu","year":"2008","journal-title":"J. Biol. Chem."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1021\/bi5015166","article-title":"Omecamtiv mecarbil modulates the kinetic and motile properties of porcine \u03b2-cardiac myosin","volume":"54","author":"Liu","year":"2015","journal-title":"Biochemistry"},{"key":"B76","doi-asserted-by":"publisher","first-page":"20579","DOI":"10.1074\/jbc.M800554200","article-title":"Functional effects of the hypertrophic cardiomyopathy R403Q mutation are different in an \u03b1- or \u03b2-myosin heavy chain backbone","volume":"283","author":"Lowey","year":"2008","journal-title":"J. Biol. Chem."},{"key":"B77","doi-asserted-by":"publisher","first-page":"16403","DOI":"10.1074\/jbc.R109.025551","article-title":"Common structural motifs for the regulation of divergent class II myosins","volume":"285","author":"Lowey","year":"2010","journal-title":"J. Biol. Chem."},{"key":"B78","volume-title":"Cardiac myosin filaments are directly regulated by calcium","author":"Ma","year":"2022"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1126\/science.1200113","article-title":"Cardiac myosin activation: A potential therapeutic approach for systolic heart failure","volume":"331","author":"Malik","year":"2011","journal-title":"Science"},{"key":"B80","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.jacc.2012.02.068","article-title":"Genetics of hypertrophic cardiomyopathy after 20 years: Clinical perspectives","volume":"60","author":"Maron","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"A16842","DOI":"10.1161\/circ.134.suppl_1.16842","article-title":"Abstract 16842: Obstructive hypertrophic cardiomyopathy: Initial single ascending dose data in healthy volunteers and patients","volume":"134","author":"Maron","year":"2016","journal-title":"Circulation"},{"key":"B82","article-title":"Redwood-HCM: A randomized, double-blind, placebo-controlled, dose-finding trial of the cardiac myosin inhibitor, aficamten","volume-title":"Obstructive hypertrophic cardiomyopathy","author":"Maron","year":"2021"},{"key":"B83","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s12265-011-9266-2","article-title":"How do mutations in contractile proteins cause the primary familial cardiomyopathies?","volume":"4","author":"Marston","year":"2011","journal-title":"J. Cardiovasc. Transl. Res."},{"key":"B84","doi-asserted-by":"publisher","first-page":"415","DOI":"10.3389\/fphys.2016.00415","article-title":"Why is there a limit to the changes in myofilament Ca2+-sensitivity associated with myopathy causing mutations?","volume":"7","author":"Marston","year":"2016","journal-title":"Front. Physiol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1172\/JCI62862","article-title":"Genetic mutations and mechanisms in dilated cardiomyopathy","volume":"123","author":"McNally","year":"2013","journal-title":"J. Clin. Investig."},{"key":"B86","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s12551-014-0151-5","article-title":"The role of super-relaxed myosin in skeletal and cardiac muscle","volume":"7","author":"McNamara","year":"2015","journal-title":"Biophys. Rev."},{"key":"B87","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1161\/CIRCRESAHA.110.223842","article-title":"Understanding cardiomyopathy phenotypes based on the functional impact of mutations in the myosin motor","volume":"111","author":"Moore","year":"2012"},{"key":"B88","first-page":"e76805","volume-title":"Hypertrophic cardiomyopathy mutations in the pliant and light chain-binding regions of the lever arm of human \u03b2-cardiac myosin have divergent effects on myosin function","author":"Morck","year":"2022"},{"key":"B89","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1085\/jgp.201010471","article-title":"Regulation of contraction in mammalian striated muscles\u2014The plot thick-ens","volume":"136","author":"Moss","year":"2010","journal-title":"J. Gen. Physiol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1161\/01.RES.0000127125.61647.4F","article-title":"Myosin crossbridge activation of cardiac thin filaments: Implications for myocardial function in Health and disease","volume":"94","author":"Moss","year":"2004","journal-title":"Circ. Res."},{"key":"B91","doi-asserted-by":"publisher","first-page":"e1500511","DOI":"10.1126\/sciadv.1500511","article-title":"Contractility parameters of human \u03b2-cardiac myosin with the hypertrophic cardiomyopathy mutation R403Q show loss of motor function","volume":"1","author":"Nag","year":"2015","journal-title":"Sci. Adv."},{"key":"B92","first-page":"e63703","volume-title":"To lie or not to lie: Super-relaxing with myosins","author":"Nag","year":"2021"},{"key":"B93","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nsmb.3408","article-title":"The myosin mesa and the basis of hypercontractility caused by hypertrophic cardiomyopathy mutations","volume":"24","author":"Nag","year":"2017","journal-title":"Nat. Struct. Mol. Biol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"B95","doi-asserted-by":"publisher","first-page":"H91","DOI":"10.1152\/ajpheart.01015.2003","article-title":"Differential cross-bridge kinetics of FHC myosin mutations R403Q and R453C in heterozygous mouse myocardium","volume":"287","author":"Palmer","year":"2004","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1023\/a:1005678905119","article-title":"R403Q and L908V mutant beta-cardiac myosin from patients with familial hypertrophic cardiomyopathy exhibit enhanced mechanical performance at the single molecule level","volume":"21","author":"Palmiter","year":"2000","journal-title":"J. Muscle Res. Cell. Motil."},{"key":"B97","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12881-015-0243-5","article-title":"Establishing disease causality for a novel gene variant in familial dilated cardiomyopathy using a functional in-vitro assay of regulated thin filaments and human cardiac myosin","volume":"16","author":"Pan","year":"2015","journal-title":"BMC Med. Genet."},{"key":"B98","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.pcad.2004.07.003","article-title":"Biology of the troponin complex in cardiac myocytes","volume":"47","author":"Parmacek","year":"2004","journal-title":"Prog. Cardiovasc. Dis."},{"key":"B99","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/s41467-017-00176-5","article-title":"Mechanistic and structural basis for activation of cardiac myosin force production by omecamtiv mecarbil","volume":"8","author":"Planelles-Herrero","year":"2017","journal-title":"Nat. Commun."},{"key":"B100","doi-asserted-by":"publisher","first-page":"101485","DOI":"10.1016\/j.jbc.2021.101485","article-title":"Microscale thermophoresis suggests a new model of regulation of cardiac myosin function via interaction with cardiac myosin-binding protein C","volume":"298","author":"Ponnam","year":"2022","journal-title":"J. Biol. Chem."},{"key":"B101","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/S0735-1097(21)01891-X","article-title":"Long-term safety of mavacamten in patients with obstructive hypertrophic cardiomyopathy: Interim results of the mava-long term extension (lte) study","volume":"77","author":"Rader","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"12650","DOI":"10.1074\/jbc.M110.156646","article-title":"Structure and interactions of myosin-binding protein C domain C0","volume":"286","author":"Ratti","year":"2011","journal-title":"J. Biol. Chem."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1073\/pnas.0913527107","article-title":"Functional diversity among a family of human skeletal muscle myosin motors","volume":"107","author":"Resnicow","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B104","doi-asserted-by":"publisher","first-page":"12705","DOI":"10.1073\/pnas.1508073112","article-title":"Contractility of single cardiomyocytes differentiated from pluripotent stem cells depends on physiological shape and substrate stiffness","volume":"112","author":"Ribeiro","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B105","doi-asserted-by":"publisher","first-page":"4019","DOI":"10.1038\/s41467-018-06191-4","article-title":"Hypertrophic cardiomyopathy disease results from disparate impairments of cardiac myosin function and auto-inhibition","volume":"9","author":"Robert-Paganin","year":"2018","journal-title":"Nat. Commun."},{"key":"B106","doi-asserted-by":"publisher","first-page":"E1796-E1804","DOI":"10.1073\/pnas.1611698114","article-title":"Heart failure drug changes the mechanoenzymology of the cardiac myosin powerstroke","volume":"114","author":"Rohde","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B107","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1161\/CIRCULATIONAHA.120.052359","article-title":"Mavacamten favorably impacts cardiac structure in obstructive hypertrophic cardiomyopathy: EXPLORER-HCM cardiac magnetic resonance substudy analysis","volume":"143","author":"Saberi","year":"2021","journal-title":"Circulation"},{"key":"B108","doi-asserted-by":"publisher","first-page":"eaax0069","DOI":"10.1126\/sciadv.aax0069","article-title":"The hypertrophic cardiomyopathy mutations R403Q and R663H increase the number of myosin heads available to interact with actin","volume":"6","author":"Sarkar","year":"2020","journal-title":"Sci. Adv."},{"key":"B109","article-title":"Hypertrophic cardiomyopathy","volume-title":"The online metabolic and molecular bases of inherited disease","author":"Seidman","year":"2019"},{"key":"B110","first-page":"743","article-title":"Identifying sarcomere gene mutations in hypertrophic cardiomyopathy: A personal history","volume-title":"Circ res","author":"Seidman","year":"2011"},{"key":"B111","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/s0092-8674(01)00242-2","article-title":"The genetic basis for cardiomyopathy: From mutation identification to mechanistic paradigms","volume":"104","author":"Seidman","year":"2001","journal-title":"Cell."},{"key":"B112","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jacc.2015.01.019","article-title":"New perspectives on the prevalence of hypertrophic cardiomyopathy","volume":"65","author":"Semsarian","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1007\/s12265-009-9129-2","article-title":"Insights into human \u03b2-cardiac myosin function from single molecule and single cell studies","volume":"2","author":"Sivaramakrishnan","year":"2009","journal-title":"J. Cardiovasc. Transl. Res."},{"key":"B114","doi-asserted-by":"publisher","first-page":"e83403","DOI":"10.1371\/journal.pone.0083403","article-title":"Effects of troponin T cardiomyopathy mutations on the calcium sensitivity of the regulated thin filament and the actomyosin cross-bridge kinetics of human \u03b2-cardiac myosin","volume":"8","author":"Sommese","year":"2013"},{"key":"B115","doi-asserted-by":"publisher","first-page":"12607","DOI":"10.1073\/pnas.1309493110","article-title":"Molecular consequences of the R453C hypertrophic cardiomyopathy mutation on human \u03b2-cardiac myosin motor function","volume":"110","author":"Sommese","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B116","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/j.bpj.2014.02.011","article-title":"Hypertrophic and dilated cardiomyopathy: Four decades of basic research on muscle lead to potential therapeutic approaches to these devastating genetic diseases","volume":"106","author":"Spudich","year":"2014","journal-title":"Biophys. J."},{"key":"B117","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1042\/BST20140324","article-title":"The myosin mesa and a possible unifying hypothesis for the molecular basis of human hypertrophic cardiomyopathy","volume":"43","author":"Spudich","year":"2015","journal-title":"Biochem. Soc. Trans."},{"key":"B118","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s00424-019-02259-2","article-title":"Three perspectives on the molecular basis of hypercontractility caused by hypertrophic cardiomyopathy mutations","volume":"471","author":"Spudich","year":"2019","journal-title":"Pflugers Arch."},{"key":"B119","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1242\/jcs.00899","article-title":"Chaperone-mediated folding and assembly of myosin in striated muscle","volume":"117","author":"Srikakulam","year":"2004","journal-title":"J. Cell. Sci."},{"key":"B120","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1042\/bj1710813","article-title":"The interaction of C-protein with heavy meromyosin and subfragment-2","volume":"171","author":"Starr","year":"1978","journal-title":"Biochem. J."},{"key":"B121","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1073\/pnas.0909468107","article-title":"Myosin ATP turnover rate is a mechanism involved in thermogenesis in resting skeletal muscle fibers","volume":"107","author":"Stewart","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B122","doi-asserted-by":"publisher","first-page":"7931","DOI":"10.1038\/ncomms8931","article-title":"Harmonic force spectroscopy measures load-dependent kinetics of individual human \u03b2-cardiac myosin molecules","volume":"6","author":"Sung","year":"2015","journal-title":"Nat. Commun."},{"key":"B123","first-page":"321","article-title":"Single-molecule dual-beam optical trap analysis of protein structure and function","volume-title":"Methods in enzymology","author":"Sung","year":"2010"},{"key":"B124","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1146\/annurev.biophys.050708.133751","article-title":"Structural and functional insights into the myosin motor mechanism","volume":"39","author":"Sweeney","year":"2010","journal-title":"Annu. Rev. Biophys."},{"key":"B125","doi-asserted-by":"publisher","first-page":"3768","DOI":"10.1074\/jbc.M116.748780","article-title":"Omecamtiv mecarbil enhances the duty ratio of human \u03b2-cardiac myosin resulting in increased calcium sensitivity and slowed force development in cardiac muscle","volume":"292","author":"Swenson","year":"2017","journal-title":"J. Biol. Chem."},{"key":"B126","first-page":"765","article-title":"Thin filament mutations: Developing an integrative approach to a complex disorder","volume-title":"Circ res","author":"Tardiff","year":"2011"},{"key":"B127","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.1172\/JCI42028","article-title":"Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-\u03b2","volume":"120","author":"Teekakirikul","year":"2010","journal-title":"J. Clin. Investig."},{"key":"B128","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/S0140-6736(11)61219-1","article-title":"Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: A first-in-man study","volume":"378","author":"Teerlink","year":"2011","journal-title":"Lancet"},{"key":"B129","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1056\/NEJMoa2025797","article-title":"Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure","volume":"384","author":"Teerlink","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B130","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.jacc.2016.01.031","article-title":"Acute treatment with omecamtiv mecarbil to increase contractility in acute heart failure: The ATOMIC-AHF study","volume":"67","author":"Teerlink","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"B131","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1016\/S0140-6736(16)32049-9","article-title":"Chronic oral study of myosin activation to increase contractility in heart failure (COSMIC-HF): A phase 2, pharmacokinetic, randomised, placebo-controlled trial","volume":"388","author":"Teerlink","year":"2016","journal-title":"Lancet"},{"key":"B132","doi-asserted-by":"publisher","first-page":"eaat1199","DOI":"10.1126\/scitranslmed.aat1199","article-title":"Hypertrophic cardiomyopathy mutations in MYBPC3 dysregulate myosin","volume":"11","author":"Toepfer","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"B133","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s12551-017-0274-6","article-title":"Hypertrophic cardiomyopathy and the myosin mesa: Viewing an old disease in a new light","volume":"10","author":"Trivedi","year":"2018","journal-title":"Biophys. Rev."},{"key":"B134","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1161\/01.RES.86.7.737","article-title":"Single-molecule mechanics of R403Q cardiac myosin isolated from the mouse model of familial hypertrophic cardiomyopathy","volume":"86","author":"Tyska","year":"2000","journal-title":"Circ. Res."},{"key":"B135","doi-asserted-by":"publisher","first-page":"9017","DOI":"10.1074\/jbc.RA118.001938","article-title":"Dilated cardiomyopathy myosin mutants have reduced force-generating capacity","volume":"293","author":"Ujfalusi","year":"2018","journal-title":"J. Biol. Chem."},{"key":"B136","doi-asserted-by":"publisher","first-page":"15058","DOI":"10.1021\/bi0495329","article-title":"Cardiac myosin isoforms from different species have unique enzymatic and mechanical properties","volume":"43","author":"Up","year":"2004","journal-title":"Biochemistry"},{"key":"B137","doi-asserted-by":"publisher","first-page":"4459","DOI":"10.1073\/pnas.93.9.4459","article-title":"The neck region of the myosin motor domain acts as a lever arm to generate movement","volume":"93","author":"Uyeda","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B138","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/0022-2836(90)90287-V","article-title":"Myosin step size estimation from slow sliding movement of actin over low densities of heavy meromyosin","volume":"214","author":"Uyeda","year":"1990","journal-title":"J. Mol. Biol."},{"key":"B139","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1172\/JCI62839","article-title":"Signaling effectors underlying pathologic growth and remodeling of the heart","volume":"123","author":"van Berlo","year":"2013","journal-title":"J. Clin. Investig."},{"key":"B140","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1093\/cvr\/cvy147","article-title":"Metabolic changes in hypertrophic cardiomyopathies: Scientific update from the working group of myocardial function of the European society of cardiology","volume":"114","author":"van der Velden","year":"2018","journal-title":"Cardiovasc. Res."},{"key":"B141","doi-asserted-by":"publisher","first-page":"e2025030118","DOI":"10.1073\/pnas.2025030118","article-title":"Hypertrophic cardiomyopathy \u03b2-cardiac myosin mutation (P710R) leads to hypercontractility by disrupting super relaxed state","volume":"118","author":"Vander Roest","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B142","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1038\/ncb1060","article-title":"Load-dependent kinetics of force production by smooth muscle myosin measured with optical tweezers","volume":"5","author":"Veigel","year":"2003","journal-title":"Nat. Cell. Biol."},{"key":"B143","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/ncb1287","article-title":"Load-dependent kinetics of myosin-V can explain its high processivity","volume":"7","author":"Veigel","year":"2005","journal-title":"Nat. Cell. Biol."},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA119.010563","article-title":"Myosin motor domains carrying mutations implicated in early or late onset hypertrophic cardiomyopathy have similar properties","author":"Vera","year":"2019","journal-title":"Biophysics"},{"key":"B145","first-page":"168","article-title":"Myosin isoforms and the mechanochemical cross-bridge cycle","volume-title":"J exp biol","author":"Walklate","year":"2016"},{"key":"B146","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1056\/NEJM199204233261703","article-title":"Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy","volume":"326","author":"Watkins","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"B147","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1080\/17431380410032481","article-title":"Molecular determinants of altered contractility in heart failure","volume":"36","author":"Wehrens","year":"2004","journal-title":"Ann. Med."},{"key":"B148","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1006\/jmbi.1999.2865","article-title":"Comparative sequence analysis of the complete human sarcomeric myosin heavy chain family: Implications for functional diversity","volume":"290","author":"Weiss","year":"1999","journal-title":"J. Mol. Biol."},{"key":"B149","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1083\/jcb.147.7.1385","article-title":"Visualization of head\u2013head interactions in the inhibited state of smooth muscle myosin","volume":"147","author":"Wendt","year":"1999","journal-title":"J. Cell. Biol."},{"key":"B150","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/ncomms1093","article-title":"Protein-binding assays in biological liquids using microscale thermophoresis","volume":"1","author":"Wienken","year":"2010","journal-title":"Nat. Commun."},{"key":"B151","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.yjmcc.2009.10.031","article-title":"Mutations in Troponin that cause HCM, DCM AND RCM: What can we learn about thin filament function?","volume":"48","author":"Willott","year":"2010","journal-title":"J. Mol. Cell. Cardiol."},{"key":"B152","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/0002-8703(67)90303-1","article-title":"Dynamics of left ventricular emptying in hypertrophic subaortic stenosis: A cineangiographic and hemodynamic study","volume":"73","author":"Wilson","year":"1967","journal-title":"Am. Heart J."},{"key":"B153","doi-asserted-by":"publisher","first-page":"7974","DOI":"10.1038\/ncomms8974","article-title":"Structural basis for drug-induced allosteric changes to human \u03b2-cardiac myosin motor activity","volume":"6","author":"Winkelmann","year":"2015","journal-title":"Nat. Commun."},{"key":"B154","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1038\/nature03920","article-title":"Atomic model of a myosin filament in the relaxed state","volume":"436","author":"Woodhead","year":"2005","journal-title":"Nature"},{"key":"B155","doi-asserted-by":"publisher","first-page":"3838","DOI":"10.1038\/s41467-018-06193-2","article-title":"Positive cardiac inotrope omecamtiv mecarbil activates muscle despite suppressing the myosin working stroke","volume":"9","author":"Woody","year":"2018","journal-title":"Nat. Commun."},{"key":"B156","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/307058a0","article-title":"Direct observation of motion of single F-actin filaments in the presence of myosin","volume":"307","author":"Yanagida","year":"1984","journal-title":"Nature"},{"key":"B157","doi-asserted-by":"publisher","first-page":"e24081","DOI":"10.7554\/eLife.24081","article-title":"Distinct contributions of the thin and thick filaments to length-dependent activation in heart muscle","volume":"6","author":"Zhang","year":"2017","journal-title":"eLife"},{"key":"B158","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1073\/pnas.0708912105","article-title":"Three-dimensional structure of vertebrate cardiac muscle myosin filaments","volume":"105","author":"Zoghbi","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."}],"updated-by":[{"DOI":"10.3389\/fphys.2022.1111059","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T00:00:00Z","timestamp":1670803200000}}],"container-title":["Frontiers in Physiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphys.2022.975076\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T12:53:43Z","timestamp":1670849623000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphys.2022.975076\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,26]]},"references-count":158,"alternative-id":["10.3389\/fphys.2022.975076"],"URL":"https:\/\/doi.org\/10.3389\/fphys.2022.975076","relation":{},"ISSN":["1664-042X"],"issn-type":[{"value":"1664-042X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,26]]},"article-number":"975076"}}